Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update


    News provided by

    BioLineRx Ltd.

    16 Aug, 2022, 14:00 IDT

    Share this article

    Share this article


    - Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks -

    - Announced appointment of commercial strategy and operations veteran Holly May as U.S.-based Chief Commercial Officer -

    - Entered into collaboration agreement with GenFleet Therapeutics to advance Motixafortide in pancreatic cancer (PDAC) -

    - Management to hold conference call today, August 16, at 10:00 am EDT -

    TEL AVIV, Israel, Aug. 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reports its financial results for the second quarter ended June 30, 2022 and provides a corporate update.

    Significant events and achievements during the second quarter 2022 and subsequent period:

    • Progressed the New Drug Application (NDA) for Motixafortide in stem cell mobilization (SCM), with submission to the FDA expected within the next 4-6 weeks;
    • Appointed commercial strategy and operations veteran Holly May as Chief Commercial Officer, based in the U.S.;
    • Continued to advance critical pre-launch activities with respect to Motixafortide commercialization in the U.S., if approved;
    • Entered into a development collaboration agreement with GenFleet Therapeutics to execute a randomized Phase 2b clinical trial of Motixafortide, in combination with anti-PD1 and chemotherapy, for first-line treatment in approximately 200 pancreatic cancer (PDAC) patients in China;
    • Ended the second quarter on solid financial footing, with cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, into the first half of 2024.

    "Since our last quarterly update, we achieved significant progress across both our Motixafortide stem cell mobilization and pancreatic cancer (PDAC) programs," stated Philip Serlin, Chief Executive Officer of BioLineRx. "With respect to stem cell mobilization, we are in the final stages of preparing for submission of our NDA to the FDA. With Holly May on board as our new Chief Commercial Officer, we are rapidly advancing critical pre-launch activities while we continue to assess all of our options with respect to commercialization of Motixafortide in the U.S., if approved."

    "The totality of data that we have compiled in stem cell mobilization, both clinical and pharmacoeconomic, make an extremely strong case for Motixafortide as the standard of care in this indication for all multiple myeloma patients undergoing autologous stem-cell transplantation, which is a highly concentrated end market estimated to be $360 million in the U.S. alone and growing consistently."

    "In PDAC, the development collaboration agreement that we announced with GenFleet builds upon the positive results from our COMBAT/KEYNOTE-202 study, and we look forward to the initiation of a randomized Phase 2b PDAC trial next year. Importantly, this collaboration allows us to advance the development of Motixafortide in PDAC while retaining rights to the molecule across all indications and geographies."

    "Finally, we are nearing a significant milestone for our second program, the anti-cancer vaccine AGI-134, with the upcoming release of proof-of-mechanism data from part 2 of a Phase 1/2a trial in solid tumors. If positive, we plan to initiate a randomized Phase 2 study next year."

    "In summary, we believe we are well-positioned to deliver several meaningful potential regulatory, commercial and clinical catalysts over the next 12-18 months," concluded Mr. Serlin.

    Upcoming Expected Milestones:

    • Submission of NDA to FDA for Motixafortide as novel mobilization agent for multiple myeloma patients undergoing autologous stem cell transplantation in next 4-6 weeks;
    • Initial results from Part 2 of Phase 1/2a trial of AGI-134 in solid tumors in H2 2022;
    • Potential FDA approval of Motixafortide in 2023;
    • Potential US launch of Motixafortide in SCM in 2023;
    • Initiation of randomized Phase 2b study in PDAC under collaboration with GenFleet in 2023;
    • Potential initiation of randomized Phase 2 study of AGI-134 in 2023.

    Financial Results for the Quarter Ended June 30, 2022: 

    Research and development expenses for the three months ended June 30, 2022 were $5.4 million, an increase of $0.3 million, or 5.0%, compared to $5.1 million for the three months ended June 30, 2021. The increase resulted primarily from an increase in expenses associated with the AGI-134 study, offset by lower expenses associated with the completed Motixafortide GENESIS trial, as well as lower expenses related to NDA supporting activities related to Motixafortide. Research and development expenses for the six months ended June 30, 2022 were $9.8 million, an increase of $0.4 million, or 4.4%, compared to $9.4 million for the six months ended June 30, 2021. The reason for the increase is similar to the aforementioned increase in the three-month period.

    Sales and marketing expenses for the three months ended June 30, 2022 were $1.2 million, an increase of $0.8 million, or 250.9% compared to $0.3 million for the three months ended June 30, 2021. The increase resulted primarily from initiation of pre-commercialization activities related to Motixafortide, as well as an increase in market research. Sales and marketing expenses for the six months ended June 30, 2022 were $1.8 million, an increase of $1.3 million, or 270.9% compared to $0.5 million for the six months ended June 30, 2021. The reason for the increase is similar to the aforementioned increase in the three-month period.

    General and administrative expenses for the three months ended June 30, 2022 were $1.0 million, similar to the comparable period in 2021. General and administrative expenses for the six months ended June 30, 2022 were $2.1 million, similar to the comparable period in 2021.

    The Company's operating loss for the three months ended June 30, 2022 amounted to $7.6 million, compared to an operating loss of $6.5 million for the comparable period in 2021. The Company's operating loss for the six months ended June 30, 2022 was $13.7 million, compared to $12.0 million for the comparable period in 2021.

    Non-operating income (expenses) for the three and six months ended June 30, 2022 and for the three and six months ended June 30, 2021 primarily relate to fair-value adjustments of warrant liabilities on the Company's balance sheet, offset by warrant offering expenses.

    Net financial expenses for the three months ended June 30, 2022 amounted to $0.3 million, compared to net financial expenses of $0.1 million for the three months ended June 30, 2021. Net financial expenses for the 2022 period primarily relate to loan interest paid and losses recorded on foreign currency (primarily NIS) cash balances due to the strengthening of the US dollar during the period, offset by investment income earned on bank deposits. Net financial expenses for the 2021 period primarily relate to loan interest paid, offset by investment income earned on bank deposits. Net financial expenses for the six months ended June 30, 2022 amounted to $0.4 million, compared to net financial expenses of $0.3 million for the six months ended June 30, 2021. The composition of the expenses is similar to the aforementioned composition detailed in the three-month periods.

    The Company's net loss for the three months ended June 30, 2022 amounted to $7.4 million, compared with a net loss of $6.8 million for the comparable period in 2021. The Company's net loss for the six months ended June 30, 2022 amounted to $12.4 million, compared with a net loss of $17.0 million for the comparable period in 2021.

    The Company held $43.2 million in cash, cash equivalents and short-term bank deposits as of June 30, 2022.

    Net cash used in operating activities was $11.9 million for the six months ended June 30, 2022, compared with net cash used in operating activities of $13.1 million for the six months ended June 30, 2021. The $1.2 million decrease in net cash used in operating activities between the two periods was primarily the result of changes in operating asset and liability items in the two periods, i.e., a smaller increase in prepaid expenses and other receivables in 2022 versus 2021, as well as an increase in accounts payable and accruals in 2022 versus decrease in the 2021 period.

    Net cash provided by investing activities was $15.1 million for the six months ended June 30, 2022, compared to net cash used in investing activities of $42.3 million for the six months ended June 30, 2021. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits.

    Net cash used in financing activities was $1.6 million for the six months ended June 30, 2022, compared to net cash provided by financing activities of $56.0 million for the six months ended June 30, 2021. The cash flows in 2022 primarily reflect the repayments of the loan from Kreos Capital. The cash flows in 2021 primarily reflect the underwritten public offering of the Company's ADSs in January 2021, warrant exercises and net proceeds from the ATM facility, offset by repayments of the loan from Kreos Capital.

    Conference Call and Webcast Information

    BioLineRx will hold a conference call today, Tuesday, August 16 at 10:00 a.m. EDT. To access the conference call, please dial +1-888-281-1167 from the US or +972-3-918-0685 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

    A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until August 18, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

    (Tables follow)

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, has successfully completed a pre-NDA meeting with the FDA, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy, and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.

    BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 16, 2022. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:
    Tim McCarthy
    LifeSci Advisors, LLC
    +1-917-679-9282
    [email protected]

    or
    Moran Meir
    LifeSci Advisors, LLC
    +972-54-476-4945
    [email protected]

    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

    (UNAUDITED)


    December 31,

    June 30,


    2021

    2022


    in USD thousands

    Assets



    CURRENT ASSETS



    Cash and cash equivalents

    12,990

    14,000

    Short-term bank deposits

    44,145

    29,146

    Prepaid expenses

    127

    717

    Other receivables

    142

    240

              Total current assets

    57,404

    44,103




    NON-CURRENT ASSETS



    Property and equipment, net

    952

    810

    Right-of-use assets, net

    1,331

    1,221

    Intangible assets, net

    21,704

    21,704

              Total non-current assets

    23,987

    23,735

              Total assets

    81,391

    67,838




    Liabilities and equity



    CURRENT LIABILITIES



    Current maturities of long-term loan

    2,757

    1,013

    Accounts payable and accruals:



         Trade

    5,567

    7,338

         Other

    1,227

    1,132

    Current maturities of lease liabilities

    168

    149

              Total current liabilities

    9,719

    9,632

    NON-CURRENT LIABILITIES



    Warrants

    1,859

    186

    Lease liabilities

    1,726

    1,452

              Total non-current liabilities

    3,585

    1,638

    COMMITMENTS AND CONTINGENT LIABILITIES



         Total liabilities

    13,304

    11,270




    EQUITY



    Ordinary shares

    21,066

    21,157

    Share premium

    339,346

    339,670

    Warrants

    975

    975

    Capital reserve

    13,157

    13,596

    Other comprehensive loss

    (1,416)

    (1,416)

    Accumulated deficit

    (305,041)

    (317,414)

              Total equity

    68,087

    56,568

              Total liabilities and equity

    81,391

    67,838

    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

    (UNAUDITED)


    Three months ended June 30,

    Six months ended June 30,


    2021

    2022

    2021

    2022


    in USD thousands

    in USD thousands

    RESEARCH AND DEVELOPMENT EXPENSES

    (5,139)

    (5,395)

    (9,417)

    (9,830)

    SALES AND MARKETING EXPENSES

    (330)

    (1,158)

    (484)

    (1,795)

    GENERAL AND ADMINISTRATIVE EXPENSES

    (1,044)

    (1,049)

    (2,061)

    (2,056)

    OPERATING LOSS

    (6,513)

    (7,602)

    (11,962)

    (13,681)

    NON-OPERATING INCOME (EXPENSES), NET

    (217)

    458

    (4,778)

    1,726

    FINANCIAL INCOME

    130

    80

    247

    147

    FINANCIAL EXPENSES

    (242)

    (379)

    (541)

    (565)

    NET LOSS AND COMPREHENSIVE LOSS

    (6,842)

    (7,443)

    (17,034)

    (12,373)







    in USD

    in USD

    LOSS PER ORDINARY SHARE - BASIC AND DILUTED

    (0.01)

    (0.01)

    (0.03)

    (0.02)






    WEIGHTED AVERAGE NUMBER OF SHARES USED IN
    CALCULATION OF LOSS PER ORDINARY SHARE

    669,138,994

    715,365,554

    614,780,845

    715,260,781

    BioLineRx Ltd.

    CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

    (UNAUDITED) 


     

    Ordinary

    Share


    Capital

    Other

    comprehensive

    Accumulated



    shares

    premium

    Warrants

    reserve

    loss

    deficit

    Total


    in USD thousands

    BALANCE AT JANUARY 1, 2021

    9,870

    279,241

    -

    12,322

    (1,416)

    (277,987)

    22,030

    CHANGES FOR SIX MONTHS ENDED
    JUNE 30, 2021:








    Issuance of share capital, net

    8,386

    37,495

    975

    -

    -

    -

    46,856

    Warrants exercised

    2,235

    18,967

    -

    -

    -

    -

    21,202

    Employee stock options exercised

    5

    41

    -

    (39)

    -

    -

    7

    Employee stock options forfeited and expired

    -

    143

    -

    (143)

    -

    -

    -

    Share-based compensation     

    -

    -

    -

    832

    -

    -

    832

    Comprehensive loss for the period

    -

    -

    -

    -

    -

    (17,034)

    (17,034)

    BALANCE AT JUNE 30, 2021

    20,496

    335,887

    975

    12,972

    (1,416)

    (295,021)

    73,893










     

    Ordinary

     

    Share


     

    Capital

    Other

    comprehensive

     

    Accumulated



    shares

    premium

    Warrants

    reserve

    loss

    deficit

    Total


    in USD thousands

    BALANCE AT JANUARY 1, 2022

    21,066

    339,346

    975

    13,157

    (1,416)

    (305,041)

    68,087

    CHANGES FOR SIX MONTHS ENDED
    JUNE 30, 2022:








    Issuance of share capital, net

    89

    177

    -

    -

    -

    -

    266

    Employee stock options exercised

    2

    12

    -

    (12)

    -

    -

    2

    Employee stock options forfeited and expired

    -

    135

    -

    (135)

    -

    -

    -

    Share-based compensation     

    -

    -

    -

    586

    -

    -

    586

    Comprehensive loss for the period

    -

    -

    -

    -

    -

    (12,373)

    (12,373)

    BALANCE AT JUNE 30, 2022

    21,157

    339,670

    975

    13,596

    (1,416)

    (317,414)

    56,568









    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

    (UNAUDITED)


     

    Ordinary

     

    Share


     

    Capital

    Other

    comprehensive

     

    Accumulated



    shares

    premium

    Warrants

    reserve

    loss

    deficit

    Total


    in USD thousands

    BALANCE AT APRIL 1, 2021

    18,731

    321,920

    975

    12,616

    (1,416)

    (288,179)

    64,647

    CHANGES FOR THREE MONTHS ENDED JUNE 30, 2021:








    Issuance of share capital, net

    1,581

    12,516

    -

    -

    -

    -

    14,097

    Warrants exercised

    184

    1,444

    -

    -

    -

    -

    1,628

    Employee stock options exercised

    -

    3

    -

    (1)

    -

    -

    2

    Employee stock options forfeited and expired

    -

    4

    -

    (4)

    -

    -

    -

    Share-based compensation     

    -

    -

    -

    361

    -

    -

    361

    Comprehensive loss for the period

    -

    -

    -

    -

    -

    (6,842)

    (6,842)

    BALANCE AT JUNE 30, 2021

    20,496

    335,887

    975

    12,972

    (1,416)

    (295,021)

    73,893










     

    Ordinary

     

    Share


     

    Capital

    Other

    comprehensive

     

    Accumulated



    shares

    premium

    Warrants

    reserve

    loss

    deficit

    Total


    in USD thousands

    BALANCE AT APRIL 1, 2022

    21,066

    339,444

    975

    13,315

    (1,416)

    (309,971)

    63,413

    CHANGES FOR THREE MONTHS ENDED
         JUNE 30, 2022:








    Issuance of share capital, net

    89

    177

    -

    -

    -

    -

    266

    Employee stock options exercised

    2

    12

    -

    (12)

    -

    -

    2

    Employee stock options forfeited and expired

    -

    37

    -

    (37)

    -

    -

    -

    Share-based compensation     

    -

    -

    -

    330

    -

    -

    330

    Comprehensive loss for the period

    -

    -

    -

    -

    -

    (7,443)

    (7,443)

    BALANCE AT JUNE 30, 2022

    21,157

    339,670

    975

    13,596

    (1,416)

    (317,414)

    56,568









    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

    (UNAUDITED)


    Six months ended June 30,


    2021

    2022


    in USD thousands




    CASH FLOWS - OPERATING ACTIVITIES



    Net loss for the period

    (17,034)

    (12,373)

    Adjustments required to reflect net cash used in operating activities
    (see appendix below)

    3,977

    498

    Net cash used in operating activities

    (13,057)

    (11,875)




    CASH FLOWS – INVESTING ACTIVITIES



    Investments in short-term deposits

    (58,000)

    (9,000)

    Maturities of short-term deposits

    15,776

    24,141

    Purchase of property and equipment

    (38)

    (62)

    Net cash provided by (used in) investing activities

    (42,262)

    15,079




    CASH FLOWS – FINANCING ACTIVITIES



    Issuance of share capital and warrants, net of issuance costs

    46,856

    266

    Exercise of warrants

    10,907

    -

    Employee stock options exercised

    7

    2

    Repayments of loan

    (1,648)

    (1,812)

    Repayments of lease liabilities

    (122)

    (88)

    Net cash provided by (used in) financing activities

    56,000

    (1,632)




    INCREASE IN CASH AND CASH EQUIVALENTS

    681

    1,572

    CASH AND CASH EQUIVALENTS - BEGINNING

       OF PERIOD

    16,831

    12,990

    EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

    (28)

    (562)

    CASH AND CASH EQUIVALENTS - END OF PERIOD

    17,484

    14,000




    BioLineRx Ltd.

    APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

    (UNAUDITED)


    Six months ended June 30,


    2021

    2022


    in USD thousands







    Adjustments required to reflect net cash used in operating activities:



    Income and expenses not involving cash flows:



    Depreciation and amortization

    362

    314

    Exchange differences on cash and cash equivalents

    28

    562

    Fair value adjustments of warrants

    4,889

    (1,673)

    Share-based compensation

    832

    586

    Interest and exchange differences on short-term deposits

    (103)

    (142)

    Interest on loan

    176

    68

    Exchange differences on lease liability 

    (26)

    (205)


    6,158

    (490)




    Changes in operating asset and liability items:



    Increase in prepaid expenses and other receivables

    (1,212)

    (688)

    Increase (decrease) in accounts payable and accruals

    (969)

    1,676


    (2,181)

    988


    3,977

    498







    Supplemental information on interest received in cash

    39

    146




    Supplemental information on interest paid in cash

    350

    217




    Supplemental information on non-cash transactions:



    Acquisition of right-of-use asset

    171

    -




    Exercise of warrants (portion related to accumulated
    fair value adjustments)

    10,295

    -




    SOURCE BioLineRx Ltd.

    Modal title

    Also from this source

    BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

    BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

    BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.